Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis

نویسندگان

  • Abdoreza Naser Moghadasi Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Samaneh Hosseini Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Tayebeh Kazemi Otolaryngology Research Center, Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
چکیده مقاله:

Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time.   Case Report: Here, we introduce a young girl, a known case of MS, who developed reversible isolated unilateral sensory-neural hearing loss along imaging activity two weeks after stopping fingolimod. The patient responded well to the intravenous corticosteroid therapy which is the first line treatment of new MS attack.   Conclusion: fingolimod cessation can cause rebound activity in a short period of the time. It is important to consider any new neurological sign and symptom as a rebound activity during washout time. Although SNHL is not common in MS, it could be presented as an unusual manifestation of rebound relapse after stopping fingolimod. 

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Sensory neural hearing loss following Tympanomastoid surgery

Objective: Generated acoustic trauma by suction and drill may cause sensorineural hearing loss after Tympanomastoid surgery. This study was carried out to determine the relationship of sensorineural hearing loss and chronic otitis media surgery at Ahvaz Jundishapur University of Medical Sciences in Iran. Material and Methods: This prospective study included 386 patients of ch...

متن کامل

Immune Rebound: Multiple Sclerosis after Treatment of Cushing’s disease

High cortisol level in endogenous Cushing’s syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. This is the second reported case of multiple sclerosis developing after treatment of Cushing’s syndrome. A 42-year old man is reported who presented with bone fracture and...

متن کامل

sensory neural hearing loss following tympanomastoid surgery

objective: generated acoustic trauma by suction and drill may cause sensorineural hearing loss after tympanomastoid surgery. this study was carried out to determine the relationship of sensorineural hearing loss and chronic otitis media surgery at ahvaz jundishapur university of medical sciences in iran. material and methods: this prospective study included 386 patients of chronic middle ear di...

متن کامل

Fingolimod and multiple sclerosis

Neurology 2012;79:1942–1943 Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting 4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without causing notable immunosuppression? Thus, any new immunomodulatory ther...

متن کامل

[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].

CASE REPORT A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and O...

متن کامل

Fingolimod treatment in multiple sclerosis

Objective: To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume. Methods: In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingo...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


عنوان ژورنال

دوره 32  شماره 4

صفحات  249- 253

تاریخ انتشار 2020-07-01

با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023